NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dex Versus Lenalidomide and Dex High- Risk SMM

• HO147SMM

• NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM (HO147SMM)

• KRd

• Rd

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM (HO147SMM)

Randomized (2:1) multi-center open-label phase II trial. Patients with high-risk SMM will be enrolled on the study and treated with KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9) or Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Multiple Locations

Europe

---

ClinicalTrials.gov Identifier: NCT03673826

Official Title: Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.

First Posted : September 17, 2018

Click here for details on ClinicalTrials.gov

HOVON HO147 MM

---

Drug: Carfilzomib

Drug: Dexamethasone

Drug: Lenalidomide

---

Location

Europe

Czechia

Italy

Netherlands

Norway